Company Research Report: Halo Therapeutics

Company Overview

Name: Halo Therapeutics

Mission: To leverage leading-edge technologies to create highly targeted small molecule treatments for diseases with significant unmet needs that cause substantial negative impact on public health.

Founded By: Founded by scientists including Dr. Dan Fitzgerald, Imre Berger, and Christiane Schaffitzel.

Key People:

Dr. Dan Fitzgerald - CEO

Prof. Imre Berger - Chief Scientific Officer (CSO)

Prof. Christiane Schaffitzel - Chief Technology Officer (CTO)

Dr. Ameet Ambarkhane - Chief Development Officer

Tony Fox, MD PhD - Chief Medical Officer (CMO)

Dr. Catherine Hyams, MBBS PhD

Prof. Adam Finn, MD PhD

Headquarters: No information is available

Number of Employees: No information is available

Revenue: No information is available

Known For: Developing innovative, highly targeted small molecule treatments and focusing on diseases with high unmet medical needs.

Products

Research and Development Focus:

Structure-Based Drug Design: Utilizes computational chemistry alongside other technologies to leverage high-resolution protein structural data.

Structural Biology: Employs technologies like X-ray crystallography and cryo-electron microscopy (cryo-EM) for atomic-resolution data.

Computational Chemistry: Focuses on physics-based analyses to design small molecule drugs.

Products and Key Features

Halo Therapeutics is advancing a pipeline of novel, proprietary therapeutics, though specific products are not explicitly listed in the provided data.

Recent Developments

New Products Launched: No specific new products are listed.

New Features Added: No specific new features are listed.

Partnerships: Engaged in partnerships, including with Oracle against COVID, and backed by institutions like the Development Bank of Wales, the KBA Group, and the Science Angels Syndicate.

Notable Achievements:

Recognition at the OBN Awards 2022.

Researchers at Halo have been involved in discovering significant insights into coronavirus behavior, such as the fatty acid binding pocket in the SARS-CoV-2 spike protein.

Recent News and Publications

Key Publications:

Research on the fatty acid binding pocket in the SARS-CoV-2 spike protein.

Structural insights into SARS-CoV-2 evolution.

News Highlights:

Development of coronavirus nasal spray in Wales.

Halo Therapeutics' scientists have published and contributed to research on the SARS-CoV-2 virus, including potential antiviral strategies and understanding structural interactions with its proteins.

Events:

February 14, 2024: Celebration of International Women in Science Day featuring Halo's CTO.

May 18, 2023: Closed Seed B fundraising round to enter clinical trials.

Disclaimer: This report is based on the information available as of the provided documents, and no additional external resources were used. Some data fields have been marked as "No information is available" due to the lack of specific details in the provided text.